相关实验视频

Updated: Jul 8, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

通过分子动力学模拟研究对AURKs抑制剂的结合选择性分析

Rima D Alharthy¹, Ghulam Fatima², Numan Yousaf²

¹Department of Chemistry, Science and Arts College, King Abdulaziz University, Jeddah, Saudi Arabia.

|December 19, 2023

概括

三种抑制剂对奥罗拉B激酶 (AURKB) 的结合亲和力比奥罗拉A激酶 (AURKA) 的结合亲和力更大. 分子动力学模拟确定了影响这种选择性的关键残留物和蛋白质灵活性,有助于癌症药物设计.

科学领域:

生物化学和分子生物学
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

光激酶 (AURKs) 是细胞分裂的关键调节者,并被认为是瘤学中重要的治疗点.
开发对AURKA和AURKB的选择性抑制剂对于有效的癌症治疗至关重要,最大限度地减少非标效应.

研究的目的:

研究三种小分子抑制剂 (HPM,MPY,VX6) 对光激酶A (AURKA) 和光激酶B (AURKB) 的结合选择性.
阐明调控这些抑制剂的差异性结合亲缘关系的分子相互作用和动态因素.

主要方法:

用分子动力学 (MD) 模拟来预测抑制剂和AURKA和AURKB之间的结合自由能量.
进行了具有约束力的能量分解分析,以确定有助于选择性的特定残留物相互作用.
用MD轨迹分析来评估抑制剂对蛋白质结构动态的影响.

主要成果:

所有三种抑制剂 (HPM,MPY,VX6) 与AURKA相比,与AURKB表现出更有利的结合相互作用.
特定的残留物对,包括 (L139,L83), (V147,V91), (L210,L154) 和 (L263,L207),被确定为选择性结合的关键.
抑制剂结合影响了蛋白质结构的动态灵活性,有助于部分选择性.

结论:

该研究成功地描述了HPM,MPY和VX6对AURKB而不是AURKA的结合选择性.
阐明了对这种选择性负责的关键分子决定因素和动态效应.
这些发现为用于癌症治疗的新型,高度选择性的AURKA/AURKB抑制剂的合理设计提供了宝贵的见解.

更多相关视频

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

相关概念视频

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...